Literature DB >> 8105125

Alpha 1-adrenoceptor subtype in the rat prostate is preferentially the alpha 1A type.

H Yazawa1, K Honda.   

Abstract

alpha 1-Adrenoceptors in the rat prostate were characterized by a binding assay using the newly synthesized radioligand [3H]-YM617 (5-[2-[[2[ethoxyring(n)-3H](o-ethoxyphenoxy)ethyl]amino]prop yl]-2-methoxybenzenesulfonamide HCl) and an in vitro assay. Specific [3H]-YM617 binding in the rat prostate was saturable and of high affinity (KD = 61.5 +/- 5.9 pM) with 23.2 +/- 6.9 fmol/mg of protein as the maximal number of binding sites (Bmax). alpha-Adrenoceptor agonists and antagonists inhibited the binding of the radioligand with the following order of effectiveness: YM617 > prazosin = bunazosin > WB4101 > 5-methylurapidil = phenoxybenzamine > phentolamine > S(+)-isomer of YM617 > yohimbine > norepinephrine > phenylephrine > methoxamine. alpha 1-Adrenoceptors in the rat prostate preferred the R(-)-isomer of YM617 to the S(+)-isomer. Preincubation with chlorethylclonidine (CEC; 10(-5) M, 10 min) just slightly changed the Bmax value for [3H]-YM617 without changing the KD value in the prostate; however, CEC reduced the Bmax in the aorta. In the isolated tissue, pretreatment with CEC (10(-5) M, 10 and 30 min) time-dependently shifted to the right the dose-response curve for phenylephrine and decreased the maximal contraction of aortas induced by phenylephrine, but did not shift or decrease those of prostates. The present results indicate that the alpha 1-adrenoceptors in the rat prostate are mainly CEC-insensitive (alpha 1A), whereas those in the aorta are CEC-sensitive (alpha 1B).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105125     DOI: 10.1254/jjp.62.297

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  7 in total

1.  Agonist pharmacology at recombinant α1A - and α1L -adrenoceptors and in lower urinary tract α1 -adrenoceptors.

Authors:  Hatsumi Yoshiki; Junsuke Uwada; Hidenori Umada; Tadashi Kobayashi; Toshihiro Takahashi; Tomio Yamakawa; Akio Yamaguchi; Osamu Yokoyama; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 2.  Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.

Authors:  A Nishimune; H Yoshiki; J Uwada; A S M Anisuzzaman; H Umada; I Muramatsu
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Characterization of alpha 1 D-adrenoceptor subtype in rat myocardium, aorta and other tissues.

Authors:  X F Deng; S Chemtob; D R Varma
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 4.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 5.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

6.  Analysis of the activity of alpha 1-adrenoceptor antagonists in rat aorta.

Authors:  P H Van der Graaf; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

7.  Upregulation of Oxytocin Receptor in the Hyperplastic Prostate.

Authors:  Zhuo Li; He Xiao; Kebing Wang; Yuelan Zheng; Ping Chen; Xinghuan Wang; Michael E DiSanto; Xinhua Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-03       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.